

---

## Expres<sup>2</sup>ion will present its Expres<sup>2</sup> technology platform at several key events in October and November

Expres<sup>2</sup>ion Biotech Holding AB and its affiliate Expres<sup>2</sup>ion Biotechnologies ApS ("Expres<sup>2</sup>ion") announce that the Company will participate at several key events in October and November, including World Vaccine Congress, October 29-31, 2018, in Lisbon, Portugal, and Sedermeradagen, November 7, 2018, in Stockholm, Sweden.

During these and additional scientific and business partnering meetings, Expres<sup>2</sup>ion will elaborate on the advantages of using the Expres<sup>2</sup> platform for vaccine discovery, development and GMP production. Recent scientific publications where the platform was used include articles on malaria vaccine development and production in the esteemed Nature journals npj Vaccines ([link to August 17, 2018 press release](#)) and Nature Communications ([link to October 3, 2018 press release](#)).

*"These events provide excellent opportunities for us to present the Expres<sup>2</sup> platform that has proven itself as a leading tool for developing difficult-to-express proteins for next generation treatments such as transmission blocking malaria vaccines. Scientific teams and biotechnology/pharmaceutical companies are welcome to book meetings with me and my fellow colleagues to discuss potential collaborations in the vaccine development and diagnostics areas,"* says Expres<sup>2</sup>ion's CEO Dr. Steen Klysner.

Expres<sup>2</sup>ion will participate in the following activities in October and November, 2018:

### **World Vaccine Congress, October 29-31, Lisbon, Portugal**

To learn more about Expres<sup>2</sup> and our proven, effective solutions for recombinant protein development and production, please visit Expres<sup>2</sup>ion at Booth #9 in the Exhibit Hall. More information at [WVC Europe's website](#).

### **BIO-Europe, November 5-7, Copenhagen, Denmark**

To pre-arrange business meetings with Expres<sup>2</sup>ion representatives, please contact us via email on [info@expres2ionbio.com](mailto:info@expres2ionbio.com). More information at [BIO-Europe's website](#).

### **Sedermeradagen, November 7, Stockholm, Sweden**

Attend the company presentation by our CEO at this investor event by reserving a seat at [Sedermeradagen's website](#).

### **PEGS Europe (Protein & Antibody Engineering Summit), November 12-16, Lisbon, Portugal**

To prearrange technical and business meetings with Expres<sup>2</sup>ion representatives, please contact us via email on [info@expres2ionbio.com](mailto:info@expres2ionbio.com). More information at [PEGS' website](#).

### **International Conference on Vaccine R&D, November 13-15, Baltimore, MA, USA**

To prearrange technical and business meetings with Expres<sup>2</sup>ion representatives, please contact us via email on [info@expres2ionbio.com](mailto:info@expres2ionbio.com). More information at [Vaccines R&D-2018's website](#).

### **Certified Adviser**

Sedermera Fondkommission is appointed as Certified Adviser for Expres<sup>2</sup>ion.

### **For further information about Expres<sup>2</sup>ion Biotech Holding AB, please contact:**

Dr. Steen Klysner, CEO

Telephone: +45 2062 9908

E-mail: [sk@expres2ionbio.com](mailto:sk@expres2ionbio.com)

**About ExpreS<sup>2</sup>ion**

ExpreS<sup>2</sup>ion Biotechnologies ApS is the fully owned Danish subsidiary of Sweden-based ExpreS<sup>2</sup>ion Biotech Holding AB with company registration number 559033-3729. The subsidiary holds a unique proprietary platform, ExpreS<sup>2</sup>, made for fast and efficient development and robust production of complex proteins with focus on new vaccines, immune therapy and diagnostics. Since it was founded in 2010, the company has produced more than 250 proteins and 35 virus-like particles (VLPs) for and in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. Additionally, ExpreS<sup>2</sup>ion develops novel vaccines & immune therapies based on a ground-breaking VLP platform through its Danish joint venture AdaptVac ApS, founded in 2017.